<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR23">
 <label>23.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Solomon</surname>
    <given-names>SR</given-names>
   </name>
   <name>
    <surname>Sizemore</surname>
    <given-names>CA</given-names>
   </name>
   <name>
    <surname>Sanacore</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>X</given-names>
   </name>
   <name>
    <surname>Brown</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Holland</surname>
    <given-names>HK</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial</article-title>
  <source>Biol Blood Marrow Transplant</source>
  <year>2012</year>
  <volume>18</volume>
  <fpage>1859</fpage>
  <lpage>66</lpage>
  <pub-id pub-id-type="doi">10.1016/j.bbmt.2012.06.019</pub-id>
  <pub-id pub-id-type="pmid">22863841</pub-id>
 </element-citation>
</ref>
